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  In	  most	  tumors,	  tumor	  associated	  macrophages	  (TAMs)	  express	  an	  M2-­‐skewed	  phenotype	  and	   are	   therefore	   associated	  with	   unfavorable	   prognosis.	   However,	   the	   impact	   of	   TAMs	   in	  colorectal	  cancer	  (CRC)	  development	  and	  outcome	  is	  still	  controversial.	  We	  first	  demonstrate,	  by	  parallel	   studies	   in	  colitis-­‐associated	  cancer	   (CAC)	  and	   in	  genetically	  driven	  ApcMin	  mouse	  models,	   that	   p50	   NF-­‐κB	   is	   essential	   for	   CRC	   development	   by	   restraining	   M1-­‐dependent	  antitumor	  response.	  In	  absence	  of	  p50	  mice	  developed	  fewer	  and	  smaller	  CRC	  lesions	  which	  express	   enhanced	   levels	   of	   M1/Th1	   cytokines/chemokines	   including	   IL-­‐12	   and	   CXCL10,	  whose	   administration	   restrained	   CAC	   development	   in	   vivo.	   Moreover	   colons	   from	   p50-­‐/-­‐	  tumor	  bearers	  showed	  a	  reduced	  number	  of	  TAMs,	  as	  opposed	  to	  increased	  NK,	  NKT,	  CD8+	  T	  cells	  and	  apoptotic	  cancer	  cells.	  Consistently,	  in	  CRC	  patients,	  high	  burden	  of	  p50+	  TAMs	  was	  associated	  with	  decreased	  M1/Th1	  inflammation	  and	  worse	  outcome	  indicating	  p50	  as	  a	  new	  candidate	  for	  prognostic	  and	  target	  therapeutic	  intervention.	  	  	  
